Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs
benzinga.com/general/biotech/25/02/43921470/axsome-says-symbravo-hits-primary-goal-in-late-stage-migraine-trial-in-patients-experiencing-inad
On Monday, Axsome Therapeutics, Inc. (NASDAQ:AXSM) announced that the EMERGE Phase 3 trial of Symbravo (MoSEIC meloxicam and rizatriptan) in patients experiencing inadequate response to oral CGRP inhibitors (most commonly used drugs for migraine) met its primary endpoint.
Symbravo…
This story appeared on benzinga.com, 2025-02-24 18:34:22.